View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 21, 2020

FDA grants EUA for Color’s Covid-19 testing technology

The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to Color to use its Loop-mediated isothermal amplification (LAMP) technology for Covid-19 testing.

The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to Color to use its Loop-mediated isothermal amplification (LAMP) technology for Covid-19 testing.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The technology helps detect the presence of the virus by amplifying segments of viral genome within Covid-19 test samples.

Furthermore, the molecular testing technology delivers test results with accuracy equivalent to reverse transcription polymerase chain reaction (RT-PCR), which is the current gold standard method.

Compared to RT-PCR testing, LAMP is 50% faster. It also requires a different set of chemical reagents, avoiding supply chain issues that have created backlogs for other test providers.

Additionally, LAMP technology lends itself more readily to high-throughput automation and rapid lab scale-up.

Color is publishing its protocol for LAMP for other labs to replicate. The company noted that the technology has been used for rapid diagnosis of certain conditions such as Zika and dengue fever.

Color CEO Othman Laraki said: “When we started mobilising Color around the Covid-19 crisis eight weeks ago, we knew that the country needed a technology-driven solution to scale its testing efforts.

“We knew that addressing our national testing shortage would require a dramatically more scalable approach to lab design, which is what led us to LAMP. Moreover, in addition to testing capacity, reopening the country and bringing people back to work safely would require a technology-driven solution to make testing truly accessible.”

The company has also collaborated with the Broad Institute of MIT and Harvard and Weill Cornell Medicine for Covid-19 testing and technology development.

Color has published a protocol for the US employers for reducing the risk of Covid-19 among their workforce as they prepare to return to work after the lockdown.

The two-phased population screening process proposed by Color suggests a monthly and weekly testing based on population size and risk to mitigate potential outbreaks.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network